Outcomes after reversed corneal graft rejection: a report from the European VISICORT project.

IF 2 Q2 OPHTHALMOLOGY
Katja C Iselin, Jesper Hjortdal, W John Armitage, Derek Tole, Uwe Pleyer, Bertrand Vabres, Matthew D Griffin, Conor C Murphy
{"title":"Outcomes after reversed corneal graft rejection: a report from the European VISICORT project.","authors":"Katja C Iselin, Jesper Hjortdal, W John Armitage, Derek Tole, Uwe Pleyer, Bertrand Vabres, Matthew D Griffin, Conor C Murphy","doi":"10.1136/bmjophth-2023-001554","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aims to describe the outcome of corneal grafts, both low risk and high risk, after successfully reversed immunological rejection.</p><p><strong>Methods: </strong>Datasets on reversed rejection episodes in penetrating and endothelial keratoplasties between 2014 and 2019 (n=876) were extracted from the Adverse Immune Signatures and their Prevention in Corneal Transplantation database, which contains the prospectively and consecutively collected corneal transplants from five European centres. Stratified by the preoperatively determined risk status for immunological rejection, the outcome parameters analysed included visual acuity, intraocular pressure, endothelial cell density and central corneal thickness before and after reversed rejection episodes.</p><p><strong>Results: </strong>Fourty-seven (52%) out of a total of 91 identified rejection episodes were successfully reversed and were available for analysis (23 penetrating and 24 endothelial keratoplasties). No statistically significant change was found for any of the parameters studied between the values before and the values 3 months after the rejection episode, irrespective of the preoperative risk status.</p><p><strong>Conclusion: </strong>The outcome of corneal grafts that survive immunological rejection may be clinically indistinguishable from the state before immunological rejection, irrespective of graft type and risk status. These findings support clinicians by providing information on prognosis after reversed rejection episodes and by giving patients realistic expectations regarding the outcome.</p>","PeriodicalId":9286,"journal":{"name":"BMJ Open Ophthalmology","volume":"9 1","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11110599/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjophth-2023-001554","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study aims to describe the outcome of corneal grafts, both low risk and high risk, after successfully reversed immunological rejection.

Methods: Datasets on reversed rejection episodes in penetrating and endothelial keratoplasties between 2014 and 2019 (n=876) were extracted from the Adverse Immune Signatures and their Prevention in Corneal Transplantation database, which contains the prospectively and consecutively collected corneal transplants from five European centres. Stratified by the preoperatively determined risk status for immunological rejection, the outcome parameters analysed included visual acuity, intraocular pressure, endothelial cell density and central corneal thickness before and after reversed rejection episodes.

Results: Fourty-seven (52%) out of a total of 91 identified rejection episodes were successfully reversed and were available for analysis (23 penetrating and 24 endothelial keratoplasties). No statistically significant change was found for any of the parameters studied between the values before and the values 3 months after the rejection episode, irrespective of the preoperative risk status.

Conclusion: The outcome of corneal grafts that survive immunological rejection may be clinically indistinguishable from the state before immunological rejection, irrespective of graft type and risk status. These findings support clinicians by providing information on prognosis after reversed rejection episodes and by giving patients realistic expectations regarding the outcome.

逆转角膜移植排斥反应后的结果:欧洲 VISICORT 项目报告。
研究目的本研究旨在描述低风险和高风险角膜移植成功逆转免疫排斥反应后的结果:从 "角膜移植中的不良免疫信号及其预防 "数据库中提取了2014年至2019年期间穿透性角膜移植和内皮性角膜移植中发生的逆转排斥反应数据集(n=876),该数据库包含了从五个欧洲中心连续收集的前瞻性角膜移植数据。根据术前确定的免疫排斥风险状况进行分层,分析的结果参数包括排斥反应发生前后的视力、眼压、内皮细胞密度和角膜中央厚度:在总共 91 例已确认的排斥反应中,有 47 例(52%)成功逆转并可用于分析(23 例穿透性角膜移植和 24 例内皮性角膜移植)。无论术前风险状况如何,排斥反应发生前和发生排斥反应 3 个月后的数值之间没有统计学意义上的明显变化:结论:无论移植角膜的类型和风险状况如何,免疫排斥反应后存活下来的角膜移植结果在临床上可能与免疫排斥反应前的状态没有区别。这些发现为临床医生提供了逆转排斥反应后的预后信息,并让患者对结果有了切合实际的期望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMJ Open Ophthalmology
BMJ Open Ophthalmology OPHTHALMOLOGY-
CiteScore
3.40
自引率
4.20%
发文量
104
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信